Comprehensive Report Forecasts RUBRACA's Impact on Ovarian Cancer Treatment Market through 2032
03 mai 2024 05h43 HE
|
Research and Markets
Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "RUBRACA Market Size, Forecast, and Drug Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The global ovarian cancer...
ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38) with the PARP inhibitor Rubraca® (rucaparib) at the National Cancer Institute
13 avr. 2020 09h00 HE
|
ProLynx LLC
SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- ProLynx LLC today announced that the first patient was treated with its PLX038 in a Phase 1B clinical trial for small-cell lung cancer at the...